

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.)*

Zynerba Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

98986X109

(CUSIP Number)

Ethan Benovitz
Genesis Capital Advisors LLC
1212 Avenue of the Americas, 19th Floor
New York, NY 10036
(646) 564-5646

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

August 5, 2015

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

PAGE 1 OF 7 PAGES

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Ethan Benovitz

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
(b)

N/A

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

	5	SOLE VOTING POWER	
			0
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER	
			788,372*
	7	SOLE DISPOSITIVE POWER	
			0
	8	SHARED DISPOSITIVE POWER	
			788,372*
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	788,372*		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*		
	N/A		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9		
	9.03%*		
12	TYPE OF REPORTING PERSON*		
	IN		

*The shares of common stock (the "Shares") of Zynerba Pharmaceuticals, Inc., a Delaware corporation (the "Company"), reported herein are held by G-TEN Partners LLC ("G-TEN"), Genesis Capital Advisors LLC ("GCA") and Genesis Asset Opportunity Fund L.P. ("GAOF"). Ethan Benovitz and Jaime Hartman, as individuals, act as co-investment managers to G-TEN. Ethan Benovitz and Jaime Hartman are also managing members of GCA and GAOF. In their capacity as co-investment managers of G-TEN, Ethan Benovitz and Jaime Hartman have the sole power to vote and the sole power to direct the disposition of all Shares held by G-TEN. In their capacities as control persons of GCA and GAOF, Ethan Benovitz and Jaime Hartman may be deemed to beneficially own Shares held by GCA and GAOF. Accordingly, for the purposes of Reg. Section 240.13d-3, Ethan Benovitz and Jaime Hartman may be deemed to beneficially own an aggregate of 788,372 Shares, or 9.03% of the Shares deemed issued and outstanding as of August 18, 2014. The beneficial ownership percentage reported herein is based on 8,733,963 Shares issued and outstanding as of August 5, 2015, as disclosed in the Company's Prospectus, as filed with the Securities and Exchange Commission on August 5, 2015. This report shall not be deemed an admission that G-TEN, GCA, GAOF or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

PAGE 2 OF 7 PAGES

1	NAME OF REPORTING PERSON		
	S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON		
	Jaime Hartman		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) <input type="checkbox"/>	
		(b) <input type="checkbox"/>	
	N/A		
3	SEC USE ONLY		

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

	5	SOLE VOTING POWER	0
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER	788,372*
	7	SOLE DISPOSITIVE POWER	0
	8	SHARED DISPOSITIVE POWER	788,372*
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	788,372*		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*		
	N/A		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9		
	9.03%*		
12	TYPE OF REPORTING PERSON*		
	IN		

* The shares of common stock (the "Shares") of Zynerba Pharmaceuticals, Inc., a Delaware corporation (the "Company"), reported herein are held by G-TEN Partners LLC ("G-TEN"), Genesis Capital Advisors LLC ("GCA") and Genesis Asset Opportunity Fund L.P. ("GAOF"). Ethan Benovitz and Jaime Hartman, as individuals, act as co-investment managers to G-TEN. Ethan Benovitz and Jaime Hartman are also managing members of GCA and GAOF. In their capacity as co-investment managers of G-TEN, Ethan Benovitz and Jaime Hartman have the sole power to vote and the sole power to direct the disposition of all Shares held by G-TEN. In their capacities as control persons of GCA and GAOF, Ethan Benovitz and Jaime Hartman may be deemed to beneficially own Shares held by GCA and GAOF. Accordingly, for the purposes of Reg. Section 240.13d-3, Ethan Benovitz and Jaime Hartman may be deemed to beneficially own an aggregate of 788,372 Shares, or 9.03% of the Shares deemed issued and outstanding as of August 18, 2014. The beneficial ownership percentage reported herein is based on 8,733,963 Shares issued and outstanding as of August 5, 2015, as disclosed in the Company's Prospectus, as filed with the Securities and Exchange Commission on August 5, 2015. This report shall not be deemed an admission that G-TEN, GCA, GAOF or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

1 NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 G-TEN Partners LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) []
 (b) []
 N/A

3 SEC USE ONLY

4	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware	
		5 SOLE VOTING POWER
		0
	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6 SHARED VOTING POWER
		566,740*
		7 SOLE DISPOSITIVE POWER
		0
		8 SHARED DISPOSITIVE POWER
		566,740*
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
		566,740*
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	
		N/A
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	
		6.49%*
12	TYPE OF REPORTING PERSON*	
		PN

* The shares of common stock (the "Shares") of Zynerva Pharmaceuticals, Inc., a Delaware corporation (the "Company"), reported herein are held by G-TEN Partners LLC ("G-TEN"), Genesis Capital Advisors LLC ("GCA") and Genesis Asset Opportunity Fund L.P. ("GAOF"). Ethan Benovitz and Jaime Hartman, as individuals, act as co-investment managers to G-TEN. Ethan Benovitz and Jaime Hartman are also managing members of GCA and GAOF. In their capacity as co-investment managers of G-TEN, Ethan Benovitz and Jaime Hartman have the sole power to vote and the sole power to direct the disposition of all Shares held by G-TEN. In their capacities as control persons of GCA and GAOF, Ethan Benovitz and Jaime Hartman may be deemed to beneficially own Shares held by GCA and GAOF. Accordingly, for the purposes of Reg. Section 240.13d-3, Ethan Benovitz and Jaime Hartman may be deemed to beneficially own an aggregate of 788,372 Shares, or 9.03% of the Shares deemed issued and outstanding as of August 18, 2014. The beneficial ownership percentage reported herein is based on 8,733,963 Shares issued and outstanding as of August 5, 2015, as disclosed in the Company's Prospectus, as filed with the Securities and Exchange Commission on August 5, 2015. This report shall not be deemed an admission that G-TEN, GCA, GAOF or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

PAGE 4 OF 7 PAGES

- Item 1(a) Name of Issuer:
Zynerva Pharmaceuticals, Inc.
- Item 1(b) Address of Issuer's Principal Executive Offices:
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
- Item 2(a) Name of Person Filing:
Ethan Benovitz
Jaime Hartman

G-TEN Partners LLC

Item 2(b) Address of the Principal Office or, if none, Residence:
1212 Avenue of the Americas, 19th Floor
New York, NY 10036

Item 2(c) Citizenship:
Ethan Benovitz -- United States
Jaime Hartman -- United States
G-TEN Partners LLC -- Delaware

Item 2(d) Title of Class of Securities:
Common Stock

Item 2(e) CUSIP Number:
98986X109

Item 3 If the Statement is being filed pursuant to Rule
13d-1(b), or 13d-2(b), check whether the person filing
is a:

Item 4 Ownership:
(a) Amount Beneficially Owned:
Ethan Benovitz -- 788,372*
Jaime Hartman -- 788,372*
G-TEN Partners LLC -- 566,740*

(b) Percent of Class:
Ethan Benovitz -- 9.03%*
Jaime Hartman -- 9.03%*
G-TEN Partners LLC -- 6.49%*

PAGE 5 OF 7 PAGES

(c) Number of shares as to which such person has:

(i) sole power to vote or direct the vote:
Ethan Benovitz -- 0
Jaime Hartman -- 0
G-TEN Partners LLC -- 0

(ii) shared power to vote or direct the vote:
Ethan Benovitz -- 788,372*
Jaime Hartman -- 788,372*
G-TEN Partners LLC -- 566,740*

(iii) sole power to dispose or to direct the
disposition of:
Ethan Benovitz -- 0
Jaime Hartman -- 0
G-TEN Partners LLC -- 0

(iv) shared power to dispose or to direct the
disposition of:
Ethan Benovitz -- 788,372*
Jaime Hartman -- 788,372*
G-TEN Partners LLC -- 566,740*

*The shares of common stock (the "Shares") of Zynerba Pharmaceuticals, Inc., a Delaware corporation (the "Company"), reported herein are held by G-TEN Partners LLC ("G-TEN"), Genesis Capital Advisors LLC ("GCA") and Genesis Asset Opportunity Fund L.P. ("GAOF"). Ethan Benovitz and Jaime Hartman, as individuals, act as co-investment managers to G-TEN. Ethan Benovitz and Jaime Hartman are also managing members of GCA and GAOF. In their capacity as co-investment managers of G-TEN, Ethan Benovitz and Jaime Hartman have the sole power to vote and the sole power to direct the disposition of all Shares held by G-TEN. In their capacities as control persons of GCA and GAOF, Ethan Benovitz and Jaime Hartman may be deemed to beneficially own Shares held by GCA and GAOF. Accordingly, for the purposes of Reg. Section 240.13d-3, Ethan Benovitz and Jaime Hartman may be deemed to beneficially own an aggregate of 788,372 Shares, or 9.03% of the Shares deemed issued and outstanding as of August 18, 2014. The beneficial ownership percentage reported herein is based on 8,733,963 Shares issued and outstanding as of August 5, 2015, as disclosed in the Company's

Prospectus, as filed with the Securities and Exchange Commission on August 5, 2015. This report shall not be deemed an admission that G-TEN, GCA, GAOF or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

PAGE 6 OF 7 PAGES

- Item 5 Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].
- Item 6 Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.
- Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

Not applicable.
- Item 8 Identification and Classification of Members of the Group:

Not applicable.
- Item 9 Notice of Dissolution of a Group:
Not applicable.
- Item 10 Certification:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ethan Benovitz

August 14, 2015

Date

/S/ ETHAN BENOVTZ

Signature

Jaime Hartman

August 14, 2015

Date

/S/ JAIME HARTMAN

Signature

G-TEN Partners LLC

August 14, 2015

Date

/S/ ETHAN BENOVIKZ

Signature

Ethan Benovitz/Managing Member

Name/Title

PAGE 7 OF 7 PAGES

EXHIBIT 1

JOINT FILING STATEMENT
STATEMENT PURSUANT TO RULE 13D-1(K) (1)

The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the common stock of Zynerba Pharmaceuticals, Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

Ethan Benovitz

August 14, 2015

Date

/S/ ETHAN BENOVTZ

Signature

Jaime Hartman

August 14, 2015

Date

/S/ JAIME HARTMAN

Signature

G-TEN Partners LLC

August 14, 2015

Date

/S/ ETHAN BENOVTZ

Signature

Ethan Benovitz/Managing Member

Name/Title